Acumen means keenness and depth of perception. That’s exactly who we are: an experienced, tenacious team singularly focused on developing targeted therapies for Alzheimer’s disease, building upon current momentum to drive the field forward and achieve even better outcomes.
Toxic amyloid-beta oligomers (AβOs) are soluble protein aggregates that accumulate in the brain. They are also shown to be a primary and persistent driver of Alzheimer’s-associated neurodegeneration.
Building on our expertise in toxic amyloid beta oligomers, Acumen is advancing Enhanced Brain Delivery™ (EBD®) technology designed to increase brain exposure of our target compounds, support subcutaneous administration, with the goal of potentially increasing the amount and widening the distribution of the therapeutic drug to cross the blood brain barrier compared to a monoclonal antibody not using EBD.
Acumen is building upon decades of research on toxic soluble amyloid beta oligomers (AβOs) to advance treatment options for Alzheimer’s disease (AD). Our most advanced candidate, sabirnetug, is a monoclonal antibody that selectively targets toxic soluble AβOs for the treatment of early AD. It is designed to have disease-modifying benefits with an improved safety profile, while additionally potentially providing symptomatic benefit for Alzheimer’s patients.
